While the amyloid and tau pathology are likely acting through different mechanisms to elicit glutamate release, these studies show a concomitant change in vesicular glutamate transporter 1 that corresponds to the elevated glutamate levels regardless of AD pathology. This evidence concerns the gene MAPT and Alzheimer disease.